Semaglutide
The FDA-approved GLP-1 receptor agonist that turned obesity into a pharmacology problem, delivering ~15% body weight loss with once-weekly dosing.
Semaglutide is a synthetic 31-amino-acid GLP-1 receptor agonist developed by Novo Nordisk and marketed as Ozempic (type 2 diabetes), Wegovy (chronic weight management), and Rybelsus (oral diabetes). It mimics the incretin hormone GLP-1 to suppress appetite, slow gastric emptying, and improve glucose-dependent insulin secretion. Structural modifications, including a C18 fatty diacid chain that reversibly binds serum albumin, extend its half-life to roughly seven days, enabling once-weekly subcutaneous injection. It is among the most extensively studied and prescribed compounds in the metabolic space, with landmark weight-loss and cardiovascular outcome data.
Class
Synthetic 31-amino-acid GLP-1 receptor agonist (acylated incretin analog)
Half-life
~7 days (168 hours), enabled by the C18 fatty diacid albumin-binding modification
Routes
Subcutaneous (weekly), Oral (daily, Rybelsus via SNAC absorption enhancer)
Category
Weight Loss & Metabolic
Researched benefits
What it's studied for
Substantial, sustained weight loss
In the STEP 1 trial, semaglutide 2.4 mg weekly produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo, with 86% of participants losing at least 5% of body weight. STEP 5 confirmed durability, maintaining roughly 15% loss through 104 weeks of continued treatment.
Appetite and 'food noise' suppression
Central GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and caloric intake, and quiets the intrusive food-related thoughts users describe as 'food noise.' The INFORM survey found median Food Noise Questionnaire scores fell from 13 to 6 after starting injectable semaglutide.
Cardiovascular event reduction
The SELECT trial (n=17,604) showed a 20% relative reduction in major adverse cardiovascular events in overweight or obese adults without diabetes, the first cardiovascular benefit demonstrated for a weight-management drug in a non-diabetic population. SUSTAIN-6 earlier showed a 26% MACE reduction in high-risk type 2 diabetes.
Glycemic control in type 2 diabetes
Semaglutide potentiates glucose-dependent insulin secretion and suppresses glucagon, reducing HbA1c by roughly 1.5–1.8 percentage points in type 2 diabetes while improving postprandial glucose regulation.
Improved cardiometabolic risk factors
Beyond weight, treatment is associated with reductions in systemic inflammation (hs-CRP fell ~37% in SELECT), blood pressure, and improved lipid profiles, reflecting broad cardiometabolic benefit.
MASH / liver benefit
In the ESSENCE phase 3 program, Wegovy 2.4 mg achieved 63% MASH resolution versus 34% with placebo, earning the first-ever GLP-1 accelerated FDA approval for non-cirrhotic MASH with stage 2-3 fibrosis in 2025.
Mechanism
How it works
Semaglutide activates glucagon-like peptide-1 (GLP-1) receptors across the hypothalamus, brainstem, and pancreas. This drives a coordinated metabolic response: appetite signals are reduced, gastric emptying is slowed (extending satiety), insulin secretion is potentiated in a glucose-dependent manner, and glucagon release is suppressed. The net effect is lower caloric intake and improved postprandial glucose regulation.
The molecule is a modified analog of native human GLP-1(7-37) with two key engineering changes. An alpha-aminoisobutyric acid (Aib) substitution at position 8 confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic degradation, and a C18 fatty diacid chain attached via a linker at the position-26 lysine enables reversible, non-covalent binding to serum albumin. This albumin binding dramatically extends the half-life to approximately seven days, enabling once-weekly subcutaneous dosing rather than the daily injections earlier GLP-1 agonists required.
Centrally, GLP-1 receptor agonism in satiety centers is thought to underlie the subjective 'food noise' quieting effect, a reduction in intrusive food-related thoughts that earlier diet drugs never reproduced. The effect is ongoing rather than curative: agonism works only while the drug is present, and discontinuation returns appetite toward baseline, which is why STEP 4 showed weight regain after stopping.
The oral formulation (Rybelsus) uses the absorption enhancer SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) to allow the peptide to cross the gastric mucosa. Despite low bioavailability (~1%), it achieves clinically meaningful glycemic control, and higher-dose oral formulations (25 mg and 50 mg) studied in the OASIS program have approached the weight loss seen with subcutaneous dosing.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
FDA-approved products (Ozempic, Wegovy) are supplied as pre-filled auto-injector pens and require no reconstitution. Research-grade and compounded lyophilized vials are reconstituted with bacteriostatic water per vendor instructions and are typically supplied ready to draw; common vial sizes are 3 mg, 5 mg, and 10 mg.
Beginner (initiation)
- Dose
- 0.25 mg
- Frequency
- Once weekly
- Timing
- Same day each week
- Duration
- 4 weeks
- Route
- Subcutaneous
The 0.25 mg starting dose is for GI tolerance, not efficacy. Move up only once side effects settle.
Intermediate (titration)
- Dose
- 0.5 mg → 1.0 mg → 1.7 mg
- Frequency
- Once weekly
- Timing
- Same day each week
- Duration
- ~4 weeks per step (weeks 5-16)
- Route
- Subcutaneous
Standard Wegovy escalation: 0.5 mg (weeks 5-8), 1.0 mg (weeks 9-12), 1.7 mg (weeks 13-16). Escalating too fast dramatically increases severe side effects.
Advanced (maintenance, weight management)
- Dose
- 2.4 mg
- Frequency
- Once weekly
- Timing
- Same day each week (week 17 onward)
- Duration
- Ongoing
- Route
- Subcutaneous
Full Wegovy therapeutic dose reached after 16-20 weeks of titration; maintain at highest tolerated dose. Weight regain is common if discontinued without lasting lifestyle change.
Diabetes (Ozempic)
- Dose
- 0.25-2.0 mg
- Frequency
- Once weekly
- Timing
- Same day each week
- Duration
- Ongoing
- Route
- Subcutaneous
Typical diabetes maintenance is 0.5-2.0 mg weekly, lower than the obesity dose.
Oral (Rybelsus)
- Dose
- 3-14 mg
- Frequency
- Once daily
- Timing
- On an empty stomach with the SNAC absorption enhancer
- Duration
- Ongoing
- Route
- Oral
Only FDA-approved oral GLP-1; used for type 2 diabetes. Higher-dose 25/50 mg oral formulations (OASIS) are under review for obesity.
- Slow dose escalation is critical to minimize gastrointestinal side effects; titration schedules span roughly 16-20 weeks.
- Inject on the same day each week; the injection day can be changed if needed provided at least 48 hours separate doses.
- Store refrigerated before first use.
- Prioritize adequate protein intake and resistance training during treatment; neglecting them leads to muscle loss alongside fat loss.
- Fatty, spicy, and heavy meals worsen GI side effects; dietary choices meaningfully influence tolerability.
- This is a chronic medication by design, not a short course; two-thirds of lost weight can return within 12 months of stopping (STEP 4).
Evidence
Research & clinical studies (8)
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Once-weekly semaglutide 2.4 mg reduced mean body weight by 14.9% over 68 weeks versus 2.4% with placebo, with 86% of participants achieving at least 5% weight loss (n=1,961).
PMID 33567185Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with established cardiovascular disease and obesity but without diabetes (n=17,604).
PMID 37351564Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Once-weekly semaglutide reduced the composite of cardiovascular death, nonfatal MI, or nonfatal stroke by 26% versus placebo in high-cardiovascular-risk type 2 diabetes (n=3,297).
PMID 27633186Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5)
Continued semaglutide 2.4 mg maintained approximately 15% total body weight loss through 104 weeks, demonstrating durability with ongoing treatment.
PMID 34170647Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey
Individuals on injectable semaglutide reported substantial reductions in food noise, with median questionnaire scores falling from 13 to 6 and 83% reporting overall treatment satisfaction.
PMID 42217114GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review
GLP-1 receptor agonists including semaglutide produced substantial weight loss and significant reductions in major cardiovascular events in high-risk populations, though direct thromboembolism evidence remained limited.
PMID 42215399Semaglutide Use in Patients Undergoing Atrial Fibrillation Ablation and Recurrent Arrhythmia: A Focused Time-to-Event Meta-analysis
Semaglutide use was associated with reduced recurrence of arrhythmias following atrial fibrillation ablation, suggesting a potential protective effect.
PMID 42217600GLP-1 receptor agonists and post-endovascular thrombectomy outcomes in acute ischemic stroke: a multicenter propensity score matched analysis
GLP-1 receptor agonist use at the time of acute stroke was associated with improved outcomes among patients undergoing endovascular thrombectomy.
PMID 42217849Combinations
Stacking & blends
Semaglutide + Tesamorelin: Targeted Fat Loss
Dual-mechanism fat loss addressing both overall caloric deficit and visceral fat
Semaglutide promotes a sustained caloric deficit and improves insulin sensitivity through appetite suppression and GLP-1-mediated metabolic effects, while tesamorelin specifically mobilizes deep abdominal visceral adipose tissue by stimulating pulsatile GH release via GHRH agonism. The two agents operate through entirely non-overlapping pathways and target different fat compartments.
Semaglutide + B12 (compounded)
Offset nausea and support energy metabolism during caloric restriction
Some compounding pharmacies co-formulate semaglutide with injectable methylcobalamin. The rationale is that injectable B12 bypasses the reduced gastric absorption that accompanies slowed gastric motility and supports energy metabolism; however, clinical evidence that B12 changes weight-loss outcomes is limited and the combination is a compounding convention rather than a validated protocol.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis
- Severe gastrointestinal disease
- Type 1 diabetes
- Pregnancy or breastfeeding
- Eating disorders (may exacerbate restriction)
- Active cancer history (listed consideration)
GI effects are usually mild-to-moderate and concentrate in the dose-escalation phase, improving with continued use and slow titration. Discontinuation due to adverse events was 7.0% on semaglutide vs 3.1% on placebo in STEP 1. Serious but rare risks include pancreatitis, gallbladder disorders (gallstones) with rapid weight loss, dehydration-mediated acute kidney injury, and worsening diabetic retinopathy with rapid glycemic improvement. A boxed warning for thyroid C-cell tumors is based on rodent studies with no confirmed human equivalent. FDA's 2026 review did not find increased suicidal ideation with GLP-1 agonists and requested removal of that warning; the EMA continues to monitor a preliminary NAION (optic-nerve) signal. FDA prescribing protocols track HbA1c, fasting glucose, calcitonin, lipase, and baseline renal and hepatic panels.
FAQ
Semaglutide — common questions
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist, FDA-approved as Ozempic (type 2 diabetes), Wegovy (obesity), and Rybelsus (oral diabetes). It is a modified version of the natural incretin hormone GLP-1, with its half-life extended to about one week by a fatty acid chain that binds serum albumin.
What is the difference between Ozempic and Wegovy?
They are the same molecule with different branding and approved doses. Ozempic is the type 2 diabetes brand (up to 2 mg weekly); Wegovy is the weight-management brand and titrates to a higher 2.4 mg maintenance dose. Rybelsus is the oral diabetes formulation.
How is semaglutide dosed for weight loss?
The Wegovy schedule climbs once a week roughly every four weeks: 0.25 mg for the first four weeks, then 0.5, 1.0, 1.7, and finally 2.4 mg as the maintenance dose. The low start is for stomach tolerance, not results; move up only once side effects calm down.
Why does semaglutide cause nausea?
GLP-1 drugs slow how fast the stomach empties, which is part of how they curb appetite, and that is what drives the nausea. It is dose-related and usually fades; slow titration is the main way to keep it manageable.
What happens if you stop taking it?
The effect is ongoing rather than curative. The STEP 4 extension showed roughly two-thirds of lost weight returns within 12 months of stopping, because appetite returns to baseline. It is designed as a chronic medication, and lasting lifestyle change is needed to hold results.
How does semaglutide compare to tirzepatide?
Semaglutide is a single GLP-1 agonist; tirzepatide is a dual GLP-1/GIP agonist. In matched trials tirzepatide produces greater weight loss (SURMOUNT-1: 22.5% at 72 weeks vs STEP 1's 14.9% at 68 weeks), and the SURMOUNT-5 head-to-head favored tirzepatide (20.2% vs 13.7%). Both are FDA-approved.
Is research-grade semaglutide the same as Ozempic or Wegovy?
No. FDA approval applies to Novo Nordisk's pharmacy-distributed products, not to research-grade semaglutide sold by third-party labs. Research-grade material is a separate supply chain with wider purity variance and no pharmacy-grade quality guarantees; independent HPLC and mass spectrometry testing are the only meaningful purity signals.
How much does semaglutide cost?
Branded Wegovy and Ozempic retail for roughly $900-1,400 per month without insurance. Compounding pharmacies offered it at about $200-500 per month during FDA-designated shortages, and research-chemical-market pricing runs a fraction of the branded price.
